CYP19A1

Protein sy'n cael ei godio yn y corff dynol gan y genyn CYP19A1 yw CYP19A1 a elwir hefyd yn Aromatase a Cytochrome P450 family 19 subfamily A member 1 (Saesneg). Segment o DNA yw'r genyn, sy'n amgodio ffwythiant arbennig. Mae'r genyn yma wedi ei leoli ar yr edefyn ôl o gromosom dynol 15, band 15q21.2.

Cytochrome P450 family 19 subfamily A member 1
Dynodwyr
Cyfenwau	cytochrome P450subfamily XIX (aromatization of androgens)flavoprotein-linked monooxygenasecytochrome P-450AROMestrogen synthetasemicrosomal monooxygenasearomataseestrogen synthasecytochrome P450family 19subfamily Apolypeptide 1CYPXIXCytochrome P450 family 19 subfamily A member 1CYP19A1cytochrome P450 19A1
Dynodwyr allanol	GeneCards: [1]
Patrwm RNA pattern Rhagor o gyfeiriadau
Orthologau
Species	Bod dynol	Llygoden
Entrez	n/a	n/a
Ensembl	n/a	n/a
UniProt	n/a	n/a
RefSeq (mRNA)	n/a	n/a
RefSeq (protein)	n/a	n/a
Lleoliad (UCSC)	n/a	n/a
PubMed search	n/a	n/a
Wicidata
Gweld/Golygu Bod dynol

Cyfystyron

Yn aml mae gan enynnau lawer o gyfystyron. Mae hyn oherwydd eu bod yn aml yn cael eu darganfod gan nifer o bobl mewn cyd-destunau gwahanol heb wybod mai'r un genynnau oeddyn nhw. Hefyd mae gan wahanol gymunedau gwyddonol safonau gwahanol ar gyfer enwi genynnau. Dyma restr o gyfystyron ar gyfer y genyn CYP19A1.

• ARO
• ARO1
• CPV1
• CYAR
• CYP19
• CYPXIX
• P-450AROM

Llyfryddiaeth

• "Preparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue. ". PLoS One. 2017. PMID 28489882.
• "The effects of Nobiletin, Hesperetin, and Letrozole in a combination on the activity and expression of aromatase in breast cancer cells. ". Cell Mol Biol (Noisy-le-grand). 2017. PMID 28364779.
• "Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer. ". Nat Genet. 2017. PMID 28112739.
• "Aromatase changes in depression: A postmortem and animal experimental study. ". Psychoneuroendocrinology. 2017. PMID 28024269.
• "Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial.". Breast Cancer Res. 2016. PMID 27825388.